Lamivudine
- Product NDC
- 50742-623
- 11-digit product format
- 507420623
- Labeler code
- 50742
- Product ID
- 50742-623_723a8db6-baa2-47f7-a352-0ed4c25a184e
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Lamivudine
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Ingenus Pharmaceuticals, LLC
- Application
- ANDA206974
- Marketing category
- ANDA
- Marketing start
- 2017-02-01
- Substance
- LAMIVUDINE
- Active strength
- 150 mg/1
- Pharmacologic classes
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Lamivudine
- Listing expiration
- 2026-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| LAMIVUDINE | 150 mg/1 |
Harmonized Identifiers#
Field, Values table| Field | Values |
|---|
| Unii | 2T8Q726O95 |
| Rxcui | 199147, 349491 |
DailyMed Product Concepts#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 50742-623-60 | Lamivudine | 60 in 1 BOTTLE, PLASTIC | TABLET | 60 | | 5 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 50742-623 | LAMIVUDINE TABLET [INGENUS PHARMACEUTICALS, LLC] | 5 | Current NDC, Legacy NDC, 1 package rows | 20181225_47f8be59-178c-4bad-96a4-a5c82784f308.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 50742-623-60 | 50742062360 | 60 TABLET in 1 BOTTLE, PLASTIC (50742-623-60) | 60 tablet | 2017-02-01 | 0000-00-00 | No | No | Current |